论文部分内容阅读
目的:观察左乙拉西坦对老年脑梗死后迟发性癫癎的疗效和安全性。方法:左乙拉西坦单药治疗新诊断的老年脑梗死后迟发性癫癎18例,起始剂量250mg,每日2次。根据疗效调整剂量,每日最大量不超过3000mg。观察癫癎发作的频率、类型及不良反应。结果:18例迟发性癫患者应用左乙拉西坦500～1500mg·d-1后有16例(88.9%)未再有癫癎发作。3例(16.7%)有嗜睡,2例(11.1%)有头昏表现,不良反应总发生率为27.8%(5/18例)。上述不良反应均未经特殊处理,在l～2个月自行消失,无一例因不良反应退出治疗。结论:左乙拉西坦是治疗老年缺血性脑卒中后迟发性癫安全、有效,而且耐受性良好的药物。
Objective: To observe the efficacy and safety of levetiracetam in the treatment of delayed epilepsy after cerebral infarction. Methods: Levetiracetam monotherapy in the treatment of newly diagnosed senile cerebral infarction delayed epilepsy in 18 cases, the initial dose of 250mg, 2 times a day. According to the efficacy of dose adjustment, the maximum daily dose of not more than 3000mg. Observe the frequency of epileptic seizures, types and adverse reactions. Results: Eighteen patients with delayed epilepsy were treated with levetiracetam 500 ~ 1500mg · d-1 after 16 cases (88.9%) without epileptic seizures. Drowsiness was found in 3 cases (16.7%), dizziness in 2 cases (11.1%), and the rate of adverse reactions was 27.8% (5/18 cases). The above adverse reactions were without special treatment, l to 2 months disappear on their own, no case of withdrawal due to adverse reactions. Conclusion: Levetiracetam is a safe, effective, and well-tolerated drug for the treatment of delayed-type epilepsy after senile ischemic stroke.